Small interfering RNA (siRNA) has emerged as a powerful tool for achieving precise and targeted gene silencing, enabling the regulation of gene expression with exceptional specificity. However, the clinical translation of siRNA therapies remains limited by the challenge of safe and efficient delivery. Conventional RNA interference (RNAi) delivery methods, including polymer-, lipid-, and nanoparticle-based systems, are often impeded by drawbacks such as immunogenicity, toxicity, scalability issues, and high production costs.

CAPSULON polymer nanocapsules present a transformative approach to overcoming these limitations. Synthesized from biocompatible polymers, CAPSULON nanocapsules encapsulate nucleic acids with high efficiency, ensuring enhanced stability, controlled release, and reduced immunogenicity. This innovative system also facilitates cellular uptake, minimizing off-target effects and maximizing therapeutic efficacy.

This study introduces CAPSULON nanocapsules as a next-generation delivery platform that leverages the principles of natural extracellular vesicles (EVs) for the safe, efficient, and non-toxic transfection of biological molecules, including siRNA. Notably, CAPSULON technology achieves effective delivery even at minimal siRNA concentrations, providing researchers with unprecedented flexibility in optimizing dosage and release kinetics for their experimental needs.

In conclusion, polymer nanocapsules such as CAPSULON represent a highly promising, non-viral gene delivery strategy with the potential to redefine therapeutic approaches in gene therapy and personalized medicine.